https://www.selleckchem.com/pr....oducts/sch-442416.ht
We also describe the challenges leading to the lack of efficacy with ICI use and discuss potential strategies to overcome those challenges including chimeric antigen receptor T-cell therapy (CAR-T therapy), bispecific T-cell therapy (BiTE), lymphocyte activation gene-3 (LAG-3) inhibitors, T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) inhibitors, vaccines, promotion of inflammatory macrophages, indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors, DNA methyltransferase inhibitors (DNMTi) and histone deacetylase inhibitors (HD
Like
Comment
Share
